Motomura Y, Chijiiwa Y, Iwakiri Y, Ochiai T, Nawata H
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Endocrinology. 1998 Jun;139(6):2869-78. doi: 10.1210/endo.139.6.6040.
Vasoactive intestinal peptide (VIP) causes relaxation of smooth muscle cells via both VIP-specific receptor coupled to nitric oxide synthase and VIP-preferring receptor coupled to adenylate cyclase. Because the mechanism of interaction among VIP, pituitary adenylate cyclase-activating peptide (PACAP), and PTH is still unclear, the characteristics of the receptors for PACAP and PTH in circular muscle cells obtained from the guinea pig cecum were investigated. The effects of an inhibitor of cAMP-dependent protein kinase [cyclic adenosine 3',5'-monophosphorothioate (Rp-cAMPS)], guanylate cyclase inhibitors, antagonists of these peptides, and the selective receptor protection on the relaxing effect produced by PACAP, VIP, and PTH were examined. PACAP-induced relaxation was significantly inhibited by a VIP antagonist, a PTH antagonist, Rp-cAMPS, and an inhibitor of particulate guanylate cyclase. VIP-induced relaxation was significantly inhibited by a PACAP antagonist and a PTH antagonist. PTH-induced relaxation was significantly inhibited by a VIP-specific receptor antagonist and Rp-cAMPS, but not by a PACAP antagonist. A PTH antagonist significantly inhibited a VIP-preferring receptor agonist-induced relaxation. The muscle cells in which cholecystokinin octapeptide and PTH receptors were protected completely abolished the inhibitory responses to VIP and PACAP. The muscle cells in which cholecystokinin octapeptide and VIP or PACAP receptors were protected completely abolished the inhibitory response to PTH. This study shows that PACAP induces relaxation of these muscle cells via both VIP-preferring receptor coupled to adenylate cyclase and PACAP-specific receptor, and that PTH induces relaxation of the muscle cells via PTH-specific receptor coupled to adenylate cyclase. In addition, the results of a selective receptor protection show that PTH does not bind to VIP receptors, and that VIP does not bind to PTH receptor. Therefore, this study first demonstrates the presence of one-way inhibitory mechanisms from the PTH-specific receptor to the VIP-preferring receptor, and from the VIP-specific receptor to the PTH-specific receptor in the mechanisms of interaction between VIP and PTH.
血管活性肠肽(VIP)通过与一氧化氮合酶偶联的VIP特异性受体和与腺苷酸环化酶偶联的VIP偏好性受体,引起平滑肌细胞松弛。由于VIP、垂体腺苷酸环化酶激活肽(PACAP)和甲状旁腺激素(PTH)之间的相互作用机制仍不清楚,因此研究了豚鼠盲肠环形肌细胞中PACAP和PTH受体的特性。研究了环磷酸腺苷依赖性蛋白激酶抑制剂[环腺苷3',5'-单磷酸硫代物(Rp-cAMPS)]、鸟苷酸环化酶抑制剂、这些肽的拮抗剂以及选择性受体保护对PACAP、VIP和PTH产生的松弛作用的影响。PACAP诱导的松弛被VIP拮抗剂、PTH拮抗剂、Rp-cAMPS和颗粒型鸟苷酸环化酶抑制剂显著抑制。VIP诱导的松弛被PACAP拮抗剂和PTH拮抗剂显著抑制。PTH诱导的松弛被VIP特异性受体拮抗剂和Rp-cAMPS显著抑制,但未被PACAP拮抗剂抑制。PTH拮抗剂显著抑制VIP偏好性受体激动剂诱导的松弛。完全保护胆囊收缩素八肽和PTH受体的肌细胞完全消除了对VIP和PACAP的抑制反应。完全保护胆囊收缩素八肽和VIP或PACAP受体的肌细胞完全消除了对PTH的抑制反应。本研究表明,PACAP通过与腺苷酸环化酶偶联的VIP偏好性受体和PACAP特异性受体诱导这些肌细胞松弛,并且PTH通过与腺苷酸环化酶偶联的PTH特异性受体诱导肌细胞松弛。此外,选择性受体保护的结果表明,PTH不与VIP受体结合,并且VIP不与PTH受体结合。因此,本研究首次证明了在VIP和PTH相互作用机制中,存在从PTH特异性受体到VIP偏好性受体以及从VIP特异性受体到PTH特异性受体的单向抑制机制。